O
Orchard Therapeutics
Hematopoietic stem cell gene therapies for rare diseases
About Orchard Therapeutics
Orchard Therapeutics, a subsidiary of Kyowa Kirin, is a global pharmaceutical company developing and commercializing potentially curative, one-time gene therapies for patients with severe and life-threatening rare diseases. The company was founded in 2015 as a spin-out from University College London (UCL), based on the research of scientific founders Professors Bobby Gaspar and Adrian Thrasher at the UCL Great Ormond Street Institute of Child Health. Dr. Gaspar, who now serves as CEO, was motivated by his work as a pediatric immunologist, seeking a safer and more effective alternative to bone marrow transplants for children with severe immune deficiencies. This led to pioneering the use of a patient's own genetically modified hematopoietic stem cells (HSCs) to correct the underlying cause of a disease.
The company's approach involves extracting a patient's blood stem cells, modifying them genetically outside the body (ex vivo) to insert a functional copy of a faulty gene, and then reinfusing them into the patient. This autologous method aims to provide a single, transformative treatment. Orchard's business model centers on the development and commercialization of these high-value therapies. Revenue is generated from the sale of its approved products. In January 2024, Orchard was acquired by Kyowa Kirin, a Japan-based global specialty pharmaceutical company, for approximately $477.6 million, to enhance Kyowa Kirin's pipeline and focus on rare diseases.
Orchard's leading product, marketed as Libmeldy® in Europe and Lenmeldy™ in the U.S., is an approved treatment for early-onset metachromatic leukodystrophy (MLD), a rare and fatal metabolic disorder. Libmeldy received approval from the European Medicines Agency (EMA) in 2020 and the U.S. Food and Drug Administration (FDA) in 2024. The company's clinical-stage pipeline includes therapies for other rare genetic disorders, such as OTL-203 for mucopolysaccharidosis type I Hurler's syndrome (MPS-IH) and OTL-201 for mucopolysaccharidosis type IIIA (MPS-IIIA). The company has also advanced programs for Wiskott-Aldrich syndrome (WAS) and adenosine deaminase severe combined immunodeficiency (ADA-SCID).
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2018
News
Open roles
Orchard Therapeutics in the London ecosystem
The Orchard Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
California Institute for Regenerative Medicine
Series A12 investors entered at this stage
F-Prime
Baillie Gifford
ORI Capital
Temasek
Cowen Group
Juda Capital
AlbionVC
Pavilion Capital Partners
Agent Capital
4BIO Capital
UCL Technology Fund
RTW Investments
Series B and later13 investors entered at this stage
Foresite Capital
Cormorant Asset Management
ArrowMark Partners
Deerfield
RA Capital Management
Perceptive Advisors
Venrock
Casdin Capital
Avidity Partners
Surveyor Capital
Farallon Capital Management
Woodline Partners
Deep Track Capital
Source: Dealroom Talent Intelligence.
Patents
6 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Orchard Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

